Advanced Accelerator Applications Completes EUR41 Million Fundraising

February 17, 2014

SAINT-GENIS-POUILLY, France, February 17, 2014 /PRNewswire/ –


        - HBM Healthcare Investments Ltd invests EUR20 million
        - The funds will be used to:
             - Accelerate the Company's international expansion, including an increased
             presence in the US
             - Finance the clinical development of its promising portfolio of innovative
             Molecular Nuclear Medicine diagnostic and therapeutic products

Advanced Accelerator Applications (“AAA” or “the Company”), a fast growing
international specialist in Molecular Nuclear Medicine (MNM), announced today that it had
successfully completed a capital increase of EUR41 million.

This capital increase will help fund expansion plans and finance clinical trials of
its promising portfolio of MNM diagnostic and therapeutic products.

The fundraising came from existing and new shareholders, including private investors
and funds such as a company of the Tamburi Investment Partners Group and the specialist
biotech and pharma investment company HBM Healthcare Investments Ltd who led the
investment with EUR20 million.

Stefano Buono, Chief Executive Officer of AAA, commented: “We are very pleased to have
completed this EUR41 million capital increase which shows strong support from current and
new shareholders. The support we continue to receive is testament to the confidence of our
shareholders in the continued growth and positive achievements of the Company and its
solid business model. The money raised will help us accelerate our international growth,
which includes the expansion of our activities in the US, and finance the development of
our promising product pipeline. We welcome HBM Healthcare Investments Ltd as a shareholder
and believe their experience in backing biotech and pharma will be of great use to guide
our strategic directions.”

Andreas Wicki, Chief Executive Officer of HBM Healthcare Investments, added: “We are
delighted to add AAA to our portfolio of promising healthcare companies.We believe that
AAA’s approach to targeted therapy is very promising and will further advance innovation
and product development in Molecular Nuclear Medicine, a niche which has been poorly
exploited until now. AAA is a fast growing company that we are excited to support and to
accompany on the way to further success.”

AAA develops and commercializes innovative diagnostic and therapeutic products. Its
main focus is on molecular imaging and personalized medicines for the treatment of
diseases such as cancer. AAA is a European leader in the production and commercialization
of PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed
Tomography) products, with 17 production and R&D facilities in Europe, Israel and North

The Company has been profitable since 2006 with the sales of its diagnostic products
and has used this positive cash flow to finance its growing portfolio of MNM products,
including Lu-DOTATATE (Lutathera(R)), which is currently in phase III clinical trials for
the treatment of Gastro-Entero-Pancreatic Neuro Endocrine Tumors (an Orphan disease) in 51
clinical centers in the US and EU. Lutathera(R) is a true example of a Theragnostic drug,
because it integrates diagnostic and therapeutic properties into the same compound,
allowing physicians to evaluate and monitor its efficacy using imaging at every
therapeutic injection, without any additional costs.

About Advanced Accelerator Applications

Advanced Accelerator Applications (AAA) is a European pharmaceutical company founded
in 2002 to develop innovative diagnostic and therapeutic products. AAA’s main focus is in
the field of Molecular Imaging and targeted, individualized therapy for the management of
patients with serious conditions (Personalized Medicine). AAA currently has 17 production
and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and
has over 270 employees in 10 countries (France, Italy, Germany, Switzerland, Spain,
Poland, Portugal, Israel, U.S., Canada). In 2013 AAA is expecting to reach revenues of
EUR56.6 million (+27% vs. 2012) and EBITDA of EUR14 million (+49% vs. 2012). For more
information please visit: http://www.adacap.com

SOURCE Advanced Accelerator Applications

Source: PR Newswire

comments powered by Disqus